ABIVAX | Sustainability Performance
Develops obefazimod and other therapies for chronic inflammatory diseases.
2013
France
51 - 200 employees
Biotechnology
$1M - 10M in revenue
Sustainability Ranking & Industry Benchmark
#7379
Overall#394
in France#151
in BiotechnologySustainability Maturity
Sustainability Intent
Overview
Reporting
Not reporting on Sustainability
Not committed to key sustainability initiatives